Jennifer Tall

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

Sally L. George, Federica Lorenzi, David S. King et al. · EBioMedicine · 2020 · 79 citations · Full text

Medicine, Genetics, Oncology +15

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Britta Vormoor, Gareth J. Veal, Martin J. Griffin et al. · Pediatric Blood & Cancer · 2016 · 33 citations · Full text

Medicine, Oncology, Pharmacology +15

Immunoassays for the quantification of <scp>ALK</scp> and phosphorylated <scp>ALK</scp> support the evaluation of on‐target <scp>ALK</scp> inhibitors in neuroblastoma

Elizabeth R. Tucker, Jennifer Tall, Laura S. Danielson et al. · Molecular Oncology · 2017 · 10 citations · Full text

Medicine, Oncology, Pharmacology +14

Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States

Sally L. George, Claire Lynn, Reda Stankunaite et al. · Cancer Discovery · 2024 · 10 citations · Full text

Medicine, Genetics, Oncology +17